The activation of estrogen signaling in breast cancer cells appeared to enhance expression of Kcnq1ot1 and repression of CDKN1C (cyclin-dependent kinase inhibitor 1C) that is concomitant with loss of Kcnq1ot1 methylation in its promoter CpG island [50]. Here, CDKN1C is linked to breast cancer.